Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT05545969 |
Title | Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma (Neo PeLeMM) |
Acronym | Neo PeLeMM |
Recruitment | Withdrawn |
Gender | both |
Phase | Phase II |
Variant Requirements | No |
Sponsors | Melanoma Institute Australia |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | AUS |